BIO-TECHNE Corp. 10-K Summary: Fiscal Year Ended June 30, 2026
Business Context and Reporting Period
This summary covers the Annual Report on Form 10-K for BIO-TECHNE Corp. (NASDAQ: TECH) for the fiscal year ended June 30, 2026. The Company develops, manufactures, and sells life science reagents, instruments, and services globally, operating through two segments: Protein Sciences (72% of net sales) and Diagnostics and Spatial Biology (28% of net sales). The Company is headquartered in Minneapolis, Minnesota, and employs approximately 3,000 people worldwide.
Key Financial Metrics
| Metric | Fiscal 2026 | Fiscal 2025 | Fiscal 2024 |
|---|---|---|---|
| Net Sales | $1,215.0 million | $1,219.6 million | $1,159.1 million |
| Net Earnings (GAAP) | $181.9 million | $73.4 million | $168.1 million |
| Diluted EPS (GAAP) | $1.16 | $0.46 | $1.05 |
| Adjusted Net Earnings (Non-GAAP) | $303.3 million | $306.5 million | $284.7 million |
| Adjusted EPS (Non-GAAP) | $1.93 | $1.92 | $1.77 |
| Gross Margin (GAAP) | 65.8% | 64.8% | 66.4% |
| Operating Cash Flow | $292.1 million | $287.6 million | $299.0 million |
| Cash and Equivalents | $264.7 million | $162.2 million | $151.8 million |
| Debt (Revolving Credit Facility) | $200.0 million | $346.0 million | $256.0 million |
Material Changes vs. Prior Period
- Revenue: Consolidated net sales remained flat year-over-year (0% growth). Organic revenue was flat, offset by a 2% favorable impact from foreign currency translation and a 2% unfavorable impact from a business held-for-sale.
- Profitability: GAAP net earnings increased 148% to $181.9 million, primarily driven by the absence of a $83.1 million impairment charge on assets held-for-sale and a $41.8 million litigation charge recorded in fiscal 2025. Adjusted net earnings decreased slightly by 1% due to unfavorable product mix and pricing pressures.
- Segment Performance:
- Protein Sciences: Net sales increased 1% to $874.6 million. Organic revenue decreased 1% due to mix and pricing pressures.
- Diagnostics and Spatial Biology: Net sales decreased 3% to $336.4 million. This decline was largely due to the exclusion of sales from a business classified as held-for-sale (Exosome Diagnostics), which had an 8% negative impact. Organic growth for the segment was 4%.
- Expenses: Selling, general, and administrative (SG&A) expenses decreased 23% to $452.4 million, largely due to the absence of the prior year's impairment and litigation charges.
Guidance, Outlook, and Material Events
- Pending Merger: On June 25, 2026, the Company entered into a definitive agreement to be acquired by Merck KGaA, Darmstadt, Germany. The transaction values the Company at $73.00 per share in cash. The merger is expected to close in late 2026 or early 2027, subject to regulatory and shareholder approvals.
- Termination Fees: If the Company terminates the agreement for a superior proposal, it must pay Merck approximately $230.5 million. If Merck terminates due to regulatory failure, it must pay the Company approximately $576.1 million.
- Restrictions: The Company is prohibited from repurchasing shares or declaring special dividends while the Merger Agreement is in effect.
- Acquisitions and Investments:
- Wilson Wolf: The Company holds a 19.9% equity interest in Wilson Wolf Corporation. A forward contract requires the Company to acquire the remaining 80.1% by December 31, 2027, or earlier if revenue/EBITDA milestones are met. The estimated payment for the remaining interest is approximately $1 billion.
- Lunaphore: Acquired in fiscal 2024 for $169.7 million; no new acquisitions occurred in fiscal 2026.
- Risks: Key risks include the potential failure or delay of the Merger, integration challenges, foreign currency fluctuations (approx. 48% of sales are international), and regulatory compliance (FDA, EU IVDR). The Company also faces pricing pressures and unfavorable product mix in its core segments.
Investor Verification Checklist
- Merger Approval Status: Verify the timeline and likelihood of receiving necessary regulatory approvals and shareholder votes for the Merck acquisition.
- Adjusted Earnings Quality: Review the reconciliation of GAAP to Non-GAAP earnings to understand the impact of excluding restructuring, amortization, and litigation costs on reported profitability.
- Wilson Wolf Milestones: Monitor Wilson Wolf's financial performance to assess the timing and certainty of the mandatory $1 billion acquisition payment.
- Organic Growth Trends: Analyze the underlying organic revenue trends, which were flat in fiscal 2026, to gauge the health of the core business absent of currency and divestiture impacts.
- Dividend Policy: Confirm the sustainability of the quarterly dividend ($0.32 per share in fiscal 2026) given the restrictions imposed by the pending Merger Agreement.